SCHEMBL2967382

SCHEMBL2967382

CCCc1ccc2c(Nc3cc(Cl)ccc3Oc3cccc(C(C)O)c3)ccnc2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.38
POLB P06746 1/20 0.38
THRB P10828 1/20 0.38
LMNA P02545 2/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
IGF1R P08069 1/20 0.35
CYP3A4 P08684 2/20 0.34
MAPK1 P28482 2/20 0.34
HSD17B10 Q99714 2/20 0.34
KDR P35968 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MLNR O43193 1/20 0.34
ABCB11 O95342 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CHRM2 P08172 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
CHRM1 P11229 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2968674 0.91 NR4A2 (0.39) NR4A2POLBTHRBLMNAMAPT
SCHEMBL2961790 0.88 IGF1R (0.42) NR4A2POLBTHRBLMNAMAPT
SCHEMBL2960808 0.84 P2RX3 (0.41) NR4A2POLBTHRBLMNAMAPT
SCHEMBL2961833 0.83 PTGDR2 (0.44) LMNAMAPTSMN1; SMN2IGF1RKDR
SCHEMBL2969143 0.83 L3MBTL1 (0.43) POLBTHRBLMNAMAPTSMN1; SMN2
SCHEMBL2960346 0.83 NR4A2 (0.40) NR4A2POLBTHRBLMNAMAPT
SCHEMBL2957831 0.82 NR1H2 (0.42) MAPTKMT2AKDR
SCHEMBL2966433 0.81 LOXL2 (0.46) LMNAMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL2970343 0.79 NR4A2 (0.39) NR4A2POLBTHRBLMNAMAPT
SCHEMBL2970337 0.79 NR4A2 (0.39) NR4A2POLBTHRBLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 NR4A2 2293/4885POLB 442/4885THRB 4833/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 NR4A2 2293/4885POLB 442/4885THRB 4833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.